ClinicalTrials.gg
RecruitingNCT06167317Updated Nov 12, 2026

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

A Phase 1 interventional study of GS-0201 and Sacituzumab Govitecan in Advanced Solid Tumors, sponsored by Gilead Sciences. Recruiting at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Nov 12, 2026First site in South Korea7 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
278
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors.

The primary objectives of this study are to:

  • To assess the safety and tolerability of GS-0201 as monotherapy and in combination with SG in participants with selected advanced solid tumors
  • To identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of GS-0201 as monotherapy and the MTD and/or the RP2D and dosing schedule of GS-0201 in combination with SG in participants with selected advanced solid tumors
02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 693 studies on the registry; 27 are open to participants now.

Of its 262 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand and give written .
  • Assigned female or male at birth, 18 years of age or older, and meet the age of majority/adulthood per local regulations.
  • (ECOG) performance status 0 to 1.
  • by (RECIST) v1.1 criteria by investigator assessment.
  • Organ function requirements:

    • Adequate hematologic function
    • Adequate hepatic function
    • Coagulation
  • Tissue requirement:

    • Parts A, B, C, and D:

      • Pre-treatment tumor tissue is required.
    • Parts A and C backfill cohorts:

      • Individuals must agree to fresh pre- and on-treatment biopsies.
  • Individuals assigned male at birth and individuals assigned female at birth and of who engage in heterosexual intercourse must agree to use protocol-specified method(s) of
  • Willing and able to comply with the requirements and restrictions in this protocol
  • Part A (GS-0201 Monotherapy Dose Escalation) Inclusion Criteria:

    • Histologically/ confirmed progressive/advanced solid tumors with selected molecular lesions.
    • Individuals must have received, been intolerant to, or been ineligible for all treatment known to confer clinical benefit or have a to receive the therapy
  • Part B (Dose Expansion) Inclusion Criteria:

    • Disease documented as:
    • Cohort B1:

      • Histologically or cytologically confirmed progressive/advanced selected solid tumor diagnoses harboring defined molecular lesions
      • Participants may potentially be required to forgo treatment with approved agent(s) to be able to participate in the study
    • Cohort B2:

      • Histologically or cytologically confirmed progressive/advanced solid tumor diagnoses harboring defined molecular lesions not included in Cohort B1
  • Part C (Dose Escalation) Inclusion Criteria:

    • Histologically or cytologically confirmed unresectable locally advanced/ selected solid tumors
  • Part D (Dose Expansion) Inclusion Criteria:

    • Disease documented as:
    • Cohort D1:

      • Histologically or cytologically confirmed unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)
    • Cohort D2:

      • Recurrent/persistent endometrial cancer

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Known to any of the study drugs, its metabolites, or formulation
  • Requirement for ongoing therapy with or use of any prohibited medications described in the protocol
  • Individuals with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with findings suggestive of MDS/AML
  • nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of GS-0201
  • The therapies listed below within the specified timeframe:

    • Major surgery (excluding minor procedures, eg, placement of vascular access, gastrointestinal/biliary stent, ) \< 4 weeks prior to planned Cycle 1 Day 1
    • Immunotherapy or biologic therapy \< 21 days prior to planned Cycle 1 Day 1
    • Chemotherapy \< 14 days prior to planned Cycle 1 Day 1, or \< 42 days for mitomycin or nitrosoureas
    • Targeted small molecule therapy \< 14 days prior to planned Cycle 1 Day 1
    • Receipt of experimental therapy within 21 days or 5 experimental treatment half-lives (whichever is longer) prior to planned Cycle 1 Day 1
    • Hormonal or other adjunctive therapy for cancers other than the cancer under evaluation in this study that started \< 14 days prior to planned Cycle 1 Day 1 are not permitted. Hormonal therapy, bisphosphonates, somatostatin analogues, and leuprolide are permitted if started ≥ 14 days prior to planned Cycle 1 Day 1
    • Radiotherapy within 2 weeks prior to planned Cycle 1 Day 1 and the radiation is not administered to a target lesion
    • Any prior allogeneic tissue/solid organ transplantation, including hematopoietic stem cell transplantation. Individuals with a history of autologous hematopoietic stem cell transplantation are also excluded
  • Have not recovered (ie, Grade 1 or lower) from AEs due to a previously administered agent
  • Prior treatment with approved or experimental prohibited agents as detailed in the protocol.
  • Diagnosis of immunodeficiency, either primary or acquired, or requires systemic (> 10 mg of prednisone daily, or equivalent). However, replacement doses, topical, ophthalmologic, and inhalational steroids are permitted
  • Have an active second
  • Have known active central nervous system (CNS)
  • Individuals with carcinomatous meningitis or primary CNS tumors are excluded regardless of clinical stability
  • Meet any of the following criteria for cardiac disease:

    • Myocardial infarction or unstable angina pectoris within 6 months of enrollment
    • History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication)
    • > 470 msec
    • Class III or greater congestive heart failure or known less than 40%
  • Meet any of the following infectious criteria:

    • Have active serious infection requiring antimicrobials
    • Have active virus (HBV) or virus (HCV), or . In individuals with a history of HBV or HCV, individuals with detectable viral loads will be excluded
    • Individuals who test positive for hepatitis B surface antigen. Individuals who test positive for hepatitis B core antibody are eligible with a negative HBV DNA by quantitative Polymerase chain reaction (PCR)
    • Individuals who test positive for HCV antibody. Individuals who test positive for HCV antibody are eligible with a negative HCV RNA by quantitative PCR
    • Individuals who test positive for HIV antibody
  • History of pneumonitis requiring treatment with corticosteroids, interstitial lung disease, or radiation pneumonitis requiring steroids
  • Symptomatic ascites or pleural effusion
  • Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations
  • Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the individuals participation in the study
  • Use of any against infectious diseases within 4 weeks (28 days) of initiation of study drug(s) (inactivated, viral vector vaccines, and messenger RNA (mRNA) vaccines are allowed; seasonal vaccines should be up to date prior to planned Cycle 1 Day 1)
  • Parts C (Dose Escalation) and D (Dose Expansion): Combination Cohorts:

    • Individuals with active chronic inflammatory bowel disease (ulcerative colitis, Crohn disease) and individuals with a history of bowel obstruction or gastrointestinal perforation within 6 months prior to planned Cycle 1 Day 1
    • Individuals who previously received topoisomerase 1 inhibitors or antibody-drug conjugates containing a topoisomerase 1 inhibitor
    • Known severe intolerance or life-threatening hypersensitivity reactions to humanized monoclonal antibodies or intravenous (IV) immunoglobulin preparations; any history of anaphylaxis; history of human anti-human antibody response

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
278 participants (estimated)

Study arms

  • Experimental
    Part A: GS-0201 Monotherapy Dose Escalation

    Participants will receive escalating doses of GS-0201 monotherapy, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.

    Drug: GS-0201

  • Experimental
    Part B: Cohort B1: GS-0201 Monotherapy Dose Expansion

    Participants with selected breast cancer indication will receive GS-0201 monotherapy at the recommended dose for expansion.

    Drug: GS-0201

  • Experimental
    Part B: Cohort B2: GS-0201 Monotherapy Dose Expansion

    Participants with selected indications not included in cohort B1 will receive GS-0201 monotherapy at the recommended dose for expansion.

    Drug: GS-0201

  • Experimental
    Part C: Dose Escalation: GS-0201 + Sacituzumab Govitecan (SG)

    Participants will receive escalating doses of GS-0201 in combination with SG, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.

    Drug: GS-0201 · Drug: Sacituzumab Govitecan

  • Experimental
    Part D: Cohort D1: Dose Expansion: GS-0201 + SG

    Participants with confirmed unresectable locally advanced or metastatic triple negative breast cancer (mTNBC) will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.

    Drug: GS-0201 · Drug: Sacituzumab Govitecan

  • Experimental
    Part D: Cohort D2: Dose Expansion: GS-0201 + SG

    Participants with recurrent/persistent endometrial cancer will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.

    Drug: GS-0201 · Drug: Sacituzumab Govitecan

Interventions

  • DrugGS-0201

    Pill administered orally

  • Administered intravenously

    Also known as: IMMU-132, Trodelvy™, GS-0132

06

What researchers measure

Primary outcomes

  1. The Number of Participants with Dose Limiting Toxicities (DLTs) During Dose Escalation

    DLTs are defined as any of the following treatment-emergent adverse events (AEs) regardless of attribution (graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0), unless clearly related to an underlying disease or extraneous causes, with onset within the DLT-evaluation period for the corresponding dose.

    Time frame: First dose up to 30 days post last dose (Up to approximately 109 weeks).

  2. The Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: First dose up to 30 days post last dose (Up to approximately 109 weeks).

  3. The Incidence of Laboratory Abnormalities

    Time frame: First dose up to 30 days post last dose (Up to approximately 109 weeks).

Secondary outcomes

  1. Pharmacokinetic (PK) Parameter: Area Under the Concentration (AUC)0-24 of GS-0201

    AUC0-24 is defined as the concentration of drug over time between time 0 and time 24 hours.

    Time frame: Predose and postdose up to end of treatment (up to 105 weeks)

  2. PK Parameter: Cmax of GS-0201

    Cmax is defined as the maximum observed drug concentration.

    Time frame: Predose and postdose up to end of treatment (up to 105 weeks)

  3. PK Parameter: Tmax of GS-0201

    Tmax is defined as the time to maximum observed concentration.

    Time frame: Predose and postdose up to end of treatment (up to 105 weeks)

  4. PK Parameter: AUC0-168 of SG (Parts C and D only)

    AUC0-168 is defined as the concentration of drug over time between time 0 and time 168 hours.

    Time frame: Predose and postdose up to end of treatment (up to 105 weeks)

  5. PK Parameter: Cmax of SG (Parts C and D only)

    Cmax is defined as the maximum observed drug concentration.

    Time frame: Predose and postdose up to end of treatment (up to 105 weeks)

  6. PK Parameter: Tmax of SG (Parts C and D only)

    Tmax is defined as the time to maximum observed concentration.

    Time frame: Predose and postdose up to end of treatment (up to 105 weeks)

  7. GS-0201 Plasma Concentrations

    Time frame: Predose and postdose up to end of treatment (up to 105 weeks)

  8. Sacituzumab Govitecan (SG) Serum Concentrations (Parts C and D only)

    Time frame: Predose and postdose up to end of treatment (up to 105 weeks)

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Sep 2028, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Dec 12, 2023
StartActual
Jan 9, 2024
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 1 site removed — first site in South Korea
Show 7 added (5 South Korea, 2 Israel)
  • Hadassah Medical Center · Jerusalem, Israel
  • Chaim Sheba Medical Center · Tel HaShomer, Israel
  • Samsung Medical Center · Gangnam-Gu, South Korea
  • National Cancer Center - Korea · Goyang-si Gyeonggi-do, South Korea
  • Samsung Medical Center · Seoul, South Korea
  • Yonsei University Severance Hospital · Seoul, South Korea
  • Asan Medical Center · Seoul, South Korea
Show 1 removed
  • Chaim Sheba Medical Center · Tel Litwinsky, Israel
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    7 sites added, 1 site removed — first site in South Korea
    Show 7 added (5 South Korea, 2 Israel)
    • Hadassah Medical Center · Jerusalem, Israel
    • Chaim Sheba Medical Center · Tel HaShomer, Israel
    • Samsung Medical Center · Gangnam-Gu, South Korea
    • National Cancer Center - Korea · Goyang-si Gyeonggi-do, South Korea
    • Samsung Medical Center · Seoul, South Korea
    • Yonsei University Severance Hospital · Seoul, South Korea
    • Asan Medical Center · Seoul, South Korea
    Show 1 removed
    • Chaim Sheba Medical Center · Tel Litwinsky, Israel
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06167317
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Dec 12, 2023
Start date
Jan 9, 2024
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Gilead Clinical Study Information Center
Contact
GileadClinicalTrials@gilead.com
1-833-445-3230 (GILEAD-0)
Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion